CN110831932A - 晶体形式的n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺 - Google Patents

晶体形式的n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺 Download PDF

Info

Publication number
CN110831932A
CN110831932A CN201880044771.7A CN201880044771A CN110831932A CN 110831932 A CN110831932 A CN 110831932A CN 201880044771 A CN201880044771 A CN 201880044771A CN 110831932 A CN110831932 A CN 110831932A
Authority
CN
China
Prior art keywords
crystalline form
trifluoromethyl
pyrazol
phenyl
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880044771.7A
Other languages
English (en)
Chinese (zh)
Inventor
比比亚·海德曼
马库斯·冯劳默尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN110831932A publication Critical patent/CN110831932A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880044771.7A 2017-07-05 2018-07-04 晶体形式的n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺 Pending CN110831932A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017066806 2017-07-05
EPPCT/EP2017/066806 2017-07-05
PCT/EP2018/068087 WO2019008034A1 (en) 2017-07-05 2018-07-04 CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE

Publications (1)

Publication Number Publication Date
CN110831932A true CN110831932A (zh) 2020-02-21

Family

ID=63079885

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880044771.7A Pending CN110831932A (zh) 2017-07-05 2018-07-04 晶体形式的n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺

Country Status (17)

Country Link
US (2) US11059803B2 (https=)
EP (1) EP3649117B1 (https=)
JP (2) JP2020525475A (https=)
KR (1) KR102645911B1 (https=)
CN (1) CN110831932A (https=)
AU (1) AU2018296423B2 (https=)
BR (1) BR112020000099A2 (https=)
CA (1) CA3067489A1 (https=)
CL (1) CL2020000002A1 (https=)
EA (1) EA202090193A1 (https=)
IL (1) IL271764B2 (https=)
MA (1) MA50972A (https=)
MY (1) MY206357A (https=)
PH (1) PH12020500040A1 (https=)
SG (1) SG11201912881SA (https=)
UA (1) UA126582C2 (https=)
WO (1) WO2019008034A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
EP3649117B1 (en) * 2017-07-05 2024-10-09 Idorsia Pharmaceuticals Ltd Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
TW202128158A (zh) 2019-12-20 2021-08-01 瑞士商愛杜西亞製藥有限公司 包含n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-環丙基)-苯基]-乙醯胺之醫藥組合物
EP4389892A4 (en) * 2021-08-17 2025-12-10 Korea Advanced Inst Sci & Tech Antisense oligonucleotide targeting the CAV3.1 gene and its uses
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414429A (zh) * 2014-06-03 2017-02-15 埃科特莱茵药品有限公司 吡唑化合物及其作为t型钙通道阻断剂的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016041892A1 (en) 2014-09-15 2016-03-24 Actelion Pharmaceuticals Ltd Triazole compounds as t-type calcium channel blockers
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
EP3649117B1 (en) * 2017-07-05 2024-10-09 Idorsia Pharmaceuticals Ltd Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414429A (zh) * 2014-06-03 2017-02-15 埃科特莱茵药品有限公司 吡唑化合物及其作为t型钙通道阻断剂的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
赵临襄: "《化学制药工艺学》", 中国医药科技出版社, pages: 405 *

Also Published As

Publication number Publication date
US20210300894A1 (en) 2021-09-30
KR20200018698A (ko) 2020-02-19
EA202090193A1 (ru) 2020-06-03
MA50972A (fr) 2020-10-14
CL2020000002A1 (es) 2020-07-31
IL271764A (en) 2020-02-27
EP3649117B1 (en) 2024-10-09
US11555025B2 (en) 2023-01-17
IL271764B1 (en) 2023-06-01
SG11201912881SA (en) 2020-01-30
JP2020525475A (ja) 2020-08-27
US11059803B2 (en) 2021-07-13
AU2018296423A1 (en) 2020-02-20
JP2023123679A (ja) 2023-09-05
BR112020000099A2 (pt) 2020-07-07
MY206357A (en) 2024-12-12
KR102645911B1 (ko) 2024-03-08
CA3067489A1 (en) 2019-01-10
US20200165221A1 (en) 2020-05-28
IL271764B2 (en) 2023-10-01
WO2019008034A1 (en) 2019-01-10
UA126582C2 (uk) 2022-11-02
EP3649117A1 (en) 2020-05-13
AU2018296423B2 (en) 2022-07-28
PH12020500040A1 (en) 2020-10-12

Similar Documents

Publication Publication Date Title
CN110831932A (zh) 晶体形式的n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺
US12227532B2 (en) Crystalline forms
WO2018188643A1 (zh) 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法
WO2021004401A1 (zh) 一种btk激酶抑制剂关键中间体的晶型及其制备方法
KR20200054169A (ko) Ror 감마의 억제제
KR20180005252A (ko) 화합물 (s)-3-｛4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시｝-프로판-1,2-디올의 결정형
US11103512B2 (en) Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
JP2023536911A (ja) Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態
CN110003058B (zh) 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
WO2016050134A1 (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
TWI711612B (zh) 氮雜雙環基取代的三唑類衍生物的可藥用鹽、晶型及製備方法
JP2006232671A (ja) 新規セレナゾリン誘導体
JP2025513526A (ja) ５Ｈピロロ［２，３－ｂ］ピラジン誘導体の多形形態、それらの調製方法、及び使用
EA052003B1 (ru) Твердые кристаллические формы ингибиторов геликазы-примазы и способ их получения
HK40009744B (en) Crystalline forms

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination